We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
QIAGEN Posts QIAstat-Dx Gastrointestinal Panel Study Results
Read MoreHide Full Article
QIAGEN N.V. (QGEN - Free Report) recently published the outcomes of a multicenter clinical study highlighting the precision of its QIAstat-Dx syndromic testing solution in the diagnosis of the causes of acute gastroenteritis.
This has been a major step for the company toward offering accurate diagnosis and treatment of gastroenteritis.
Study Results in Details
The study proved that the QIAstat-Dx Gastrointestinal Panel was highly sensitive (98.2% positive percent agreement, a measure of ability to detect pathogens) and specific (99.9% negative percent agreement, a measure of ability to identify true negative samples). The panel could successfully identify multiple pathogens in nearly one-third of the patient samples that tested positive.
The study also demonstrated the ability of the QIAstat-Dx panel to provide cycle threshold (CT) values and amplification curves. This provides the system an edge in inferring diagnostic findings for gastrointestinal syndromes, which can be distorted by co-infections or false positives in testing. The company noted that other currently-existing syndromic platforms are not equipped to offer these facilities.
Introduced in Europe (in early 2018) and the United States (in mid-2019), the QIAstat-Dx system facilitates swift, cost-efficient and easy-to-use syndromic testing with novel Sample to Insight solutions. The QIAstat-Dx Gastrointestinal Panel provides differential diagnosis of more than 20 bacterial, viral and parasitic pathogens resulting in gut infections.
Market Prospects
Per Grand View Research, the global gastrointestinal therapeutics market was valued at $51.9 billion in 2016 and is expected to see a CAGR of 6.6% over the forecast period of 2018-2025. Hence, the study results come at an ideal time.
Recent Developments
Lately, the company has been investing in a few developments pertaining to the QIAstat-Dx system.
In May 2019, QIAGEN announced the U.S. launch of the QIAstat-Dx syndromic testing system after attaining 510(k) clearance by the FDA. Specifically, the company launched the multiplex QIAstat-Dx Respiratory Panel for simultaneous qualitative diagnosis and identification of multiple respiratory viral and bacterial pathogens.
Price Performance
In the past year, the stock has declined 7.6% compared with the broader industry’s fall of 24%.
Medtronic’s long-term earnings growth rate is expected to be 7.13%.
Baxter’s long-term earnings growth rate is projected at 12.8%.
NuVasive’s long-term earnings growth rate is expected to be 12.75%.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%. This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
Image: Bigstock
QIAGEN Posts QIAstat-Dx Gastrointestinal Panel Study Results
QIAGEN N.V. (QGEN - Free Report) recently published the outcomes of a multicenter clinical study highlighting the precision of its QIAstat-Dx syndromic testing solution in the diagnosis of the causes of acute gastroenteritis.
This has been a major step for the company toward offering accurate diagnosis and treatment of gastroenteritis.
Study Results in Details
The study proved that the QIAstat-Dx Gastrointestinal Panel was highly sensitive (98.2% positive percent agreement, a measure of ability to detect pathogens) and specific (99.9% negative percent agreement, a measure of ability to identify true negative samples). The panel could successfully identify multiple pathogens in nearly one-third of the patient samples that tested positive.
The study also demonstrated the ability of the QIAstat-Dx panel to provide cycle threshold (CT) values and amplification curves. This provides the system an edge in inferring diagnostic findings for gastrointestinal syndromes, which can be distorted by co-infections or false positives in testing. The company noted that other currently-existing syndromic platforms are not equipped to offer these facilities.
Introduced in Europe (in early 2018) and the United States (in mid-2019), the QIAstat-Dx system facilitates swift, cost-efficient and easy-to-use syndromic testing with novel Sample to Insight solutions. The QIAstat-Dx Gastrointestinal Panel provides differential diagnosis of more than 20 bacterial, viral and parasitic pathogens resulting in gut infections.
Market Prospects
Per Grand View Research, the global gastrointestinal therapeutics market was valued at $51.9 billion in 2016 and is expected to see a CAGR of 6.6% over the forecast period of 2018-2025. Hence, the study results come at an ideal time.
Recent Developments
Lately, the company has been investing in a few developments pertaining to the QIAstat-Dx system.
In May 2019, QIAGEN announced the U.S. launch of the QIAstat-Dx syndromic testing system after attaining 510(k) clearance by the FDA. Specifically, the company launched the multiplex QIAstat-Dx Respiratory Panel for simultaneous qualitative diagnosis and identification of multiple respiratory viral and bacterial pathogens.
Price Performance
In the past year, the stock has declined 7.6% compared with the broader industry’s fall of 24%.
Zacks Rank & Key Picks
QIAGEN currently carries a Zacks Rank #4 (Sell).
A few better-ranked stocks in the broader medical space are Medtronic (MDT - Free Report) , Baxter (BAX - Free Report) and NuVasive Corporation , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Medtronic’s long-term earnings growth rate is expected to be 7.13%.
Baxter’s long-term earnings growth rate is projected at 12.8%.
NuVasive’s long-term earnings growth rate is expected to be 12.75%.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%. This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
See their latest picks free >